Primary Open Angle GlaucomaPhase 1/2NCT00476138
Effect of Epigallocatechin-Gallate on Inner Retinal Function in Ocular Hypertension and Early Glaucoma
A Phase 1/2 study testing Epigallocatechin-gallate in people with Primary Open Angle Glaucoma and Ocular Hypertension, run by Catholic University of the Sacred Heart at 1 site in Italy.
Trial summary
The present study attempts to evaluate the potential beneficial effects of a flavonoid, the epigallocatechingallate, on retinal ganglion cell function, evaluated by pattern electroretinogram, in subjects with ocular hypertension or early glaucoma. Read more about this study
- Who is it for?
- Ages 35 to 60 years
- Conditions the study is for
- Primary Open Angle Glaucoma, Ocular Hypertension
- What is being tested?
- Epigallocatechin-gallate
- How many people
- 40 participants
- Where
- 1 siteItaly
- Study dates
- Nov 2006to Jul 2008
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- IOP > 21 mmHg at the time of diagnosis
- Response to ipotensive therapy
- No visible alterations of the optical nerve head (if OHT)
- Visual field: normal (if OHT), < -6dB at diagnosis (if POAG)
- Alterations in PERG
- Familiarity for glaucoma (if OHT)
Who cannot join
- Change of ipotensive therapy
- Ocular surgery
- Other ocular pathologies
- Smokers
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
Catholic University, Policlinico A. Gemelli (Hospital)
Rome, 00168
Benedetto Falsini, M.D., 01139-06-3015 ext. 4929, icloc@rm.unicatt.it
About this study
Official title: Functional Effects of Epigallocatechingallate on Retinal Function in Glaucoma
The present study attempts to evaluate the potential beneficial effects of a flavonoid, the epigallocatechingallate, on retinal ganglion cell function, evaluated by pattern electroretinogram, in subjects with ocular hypertension or early glaucoma.
Read the detailed description
Twenty ocular hypertension and twenty early open angle glaucoma patients will be randomly divided into two groups: 1. placebo group [ocular hypertension, n = 10, early glaucoma (n=10)], taking an oral placebo in addition to standard beta-blocker treatment for ocular hypertension; 2. Treatment group [ocular hypertension, n = 10, early glaucoma (n=10)], taking Epigallocatechingallate oral treatment (200 mg/day) in addition to standard beta-blocker treatment for ocular hypertension. The patients will undergo standard clinical examination including automated Humphrey perimetry (30-2), pattern electroretinogram recording and measurement of retinal nerve fiber layer thickness by Optical Coherence Tomography (OCT stratus) at baseline, 3 and 6 months of treatment and follow-up. All patients will be again tested at 3 and 6 months after changing, in a cross-over design, placebo with drug assumption and vice versa.
Main outcome measure will be pattern electroretinogram amplitude. Secondary measures will be Humphrey perimetry mean deviation and corrected pattern standard deviation, and the thickness of optic nerve fibers measured by OCT.
Pattern Electroretinogram recordings.
Stimuli will be horizontal gratings of 1.6 cycles/degree spatial frequency, modulated in counterphase at 8.14 Hz and electronically generated on a high-resolution TV monitor (contrast: 70%; mean luminance: 80 cd/m2; field size: 31° [width] x 24° [height]). Subjects fixate at the center of the stimulating field with natural pupils, whose size will be measured, at a viewing distance of 57 cm. The subjects or patients will wear full refractive correction for the test distance. Signals will be recorded by a standard, flat-cup, 9 mm Ag/AgCl electrode taped on the skin of the lower eyelid. A similar electrode, placed over the eyelid of the contralateral, unstimulated eye, will be used as reference. Responses will be amplified (100, 000), bandpass filtered (1-30 Hz), sampled with a resolution of 12 bits and averaged (250 events) with automatic artifact rejection. Two replications will be obtained for each record to verify reproducibility. Peak-to-peak amplitude (in microV) of the Fourier analyzed response 2nd harmonic will be measured.
Retinal Nerve Fiber Thickness by OCT
All patients will undergo OCT imaging (software version 4.0.1, Carl Zeiss Meditec Ophthalmic Systems Inc, Dublin, CA) of the peripapillary RNFL. The instrument will be properly aligned after the subjects are comfortably seated with their head and chin firmly positioned against the relative rests. The OCT lens will be adjusted for the patient's refractive error. The subject will be instructed to stare at the internal fixation target with the eye under examination, to enable the optic disc to come into the window and to be successively centered. The Z-offset and the polarization will be adjusted to optimize the axial interval to the OCT scan and to maximize the reflective signal, respectively. The scan protocol will be the fast RNFL thickness 3.4 (3 circular scans consecutively performed, each 3.46 mm in diameter, centered on the optic disc and averaged to form a mean baseline). All scans will be acquired five times per eye during the same day, with short breaks between measurements, under dark room conditions. Images with eye movements during scans, poor centration, poor focus, or a signal strength less than 7/10 were excluded. The mean of 3 separate RNFL measurements (256 A-scans each) with the best optic disc centration, reproducibility of the signal profiles and signal strength will be used. Retinal thickness will be measured with the location of the vitreoretinal interface and the retinal pigment epithelium defining the inner and outer boundaries of the retina, respectively. The boundaries of the RNFL will be defined by first determining the thickness of the neurosensory retina. The location of the posterior boundary of the RNFL will be determined by evaluating each A-scan for a threshold chosen to be 15 dB greater than the filtered maximum reflectivity of the adjacent retina. Various machine-generated parameters will be used for evaluation of RNFL thickness, including RNFL average thickness over the entire cylindrical section and average RNFL thickness in each quadrant (inferior, superior, temporal and nasal). Abnormal RNFL measurements using OCT will be defined as mean or quadrantic thickness values outside 95% normal limits, based on the instrument's normative age-matched database, that will be confirmed on at least three out of five repeat scans. The reference values obtained from the normal control group included in the study will be also considered. The average RNFL thickness, inferior RNFL thickness, and the superior RNFL thickness have been shown to be the best discriminators for glaucoma by the Stratus OCT. These three measures will be the RNFL parameters analyzed in our study. One author (DM) will perform all the image acquisitions.
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension
- Being tested
- Epigallocatechin-gallate
- Keywords
- Epigallocatechin-Gallate, Glaucoma, Optic Nerve, Pattern Electroretinogram, Retinal Ganglion Cells
- Medical subject headings
- Glaucoma, Open-Angle, Ocular Hypertension, Glaucoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Epigallocatechin-gallateDrug
What is being measured
The primary outcome is the main question the study is designed to answer.
PERG
Measured: six months
Secondary outcomes (2)
IOP
Measured: six months
Optical Coherence Tomography measurements of retinal nerve fiber layer thickness
Measured: six months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 May 2007 (estimated)
- Study startNov 2006
- Study completionJul 2008 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Primary Open Angle GlaucomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Catholic University of the Sacred Heart
- Sponsor type
- University, hospital or other
- Investigators
- Benedetto Falsini, MD, Principal investigator, Chatolic University of Sacred Heart, RomaTommaso Salgarello, M.D., Principal investigator, Catholic University, ItalyDario Marangoni, M.D., Principal investigator, Catholic University, Italy
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00476138
- Sponsor's protocol ID
- FISIONERVE-01
- Status last verified
- May 2007
- First submitted
- 18 May 2007
- Last updated
- 21 May 2007
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Salgarello T, Colotto A, Falsini B, Buzzonetti L, Cesari L, Iarossi G, Scullica L. Correlation of pattern electroretinogram with optic disc cup shape in ocular hypertension. Invest Ophthalmol Vis Sci. 1999 Aug;40(9):1989-97.
PubMed 10440253Colotto A, Falsini B, Salgarello T, Iarossi G, Galan ME, Scullica L. Photopic negative response of the human ERG: losses associated with glaucomatous damage. Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2205-11.
PubMed 10892864Falsini B, Marangoni D, Salgarello T, Stifano G, Montrone L, Di Landro S, Guccione L, Balestrazzi E, Colotto A. Effect of epigallocatechin-gallate on inner retinal function in ocular hypertension and glaucoma: a short-term study by pattern electroretinogram. Graefes Arch Clin Exp Ophthalmol. 2009 Sep;247(9):1223-33. doi: 10.1007/s00417-009-1064-z. Epub 2009 Mar 17.
PubMed 19290537
Study at a glance
From the registry record, last updated by the sponsor on 21 May 2007. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Functional Effects of Epigallocatechingallate on Retinal Function in Glaucoma
- ClinicalTrials.gov ID
- NCT00476138
- Acronym / sponsor ID
- FISIONERVE-01
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension
- Keywords
- Epigallocatechin-Gallate, Glaucoma, Optic Nerve, Pattern Electroretinogram, Retinal Ganglion Cells
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Catholic University of the Sacred HeartUniversity, hospital or other
- Study start
- Nov 2006
- Study completion
- Jul 2008 (estimated)
- First posted
- 21 May 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The present study attempts to evaluate the potential beneficial effects of a flavonoid, the epigallocatechingallate, on retinal ganglion cell function, evaluated by pattern electroretinogram, in subjects with ocular hypertension or early glaucoma.
Detailed description
Twenty ocular hypertension and twenty early open angle glaucoma patients will be randomly divided into two groups: 1. placebo group [ocular hypertension, n = 10, early glaucoma (n=10)], taking an oral placebo in addition to standard beta-blocker treatment for ocular hypertension; 2. Treatment group [ocular hypertension, n = 10, early glaucoma (n=10)], taking Epigallocatechingallate oral treatment (200 mg/day) in addition to standard beta-blocker treatment for ocular hypertension. The patients will undergo standard clinical examination including automated Humphrey perimetry (30-2), pattern electroretinogram recording and measurement of retinal nerve fiber layer thickness by Optical Coherence Tomography (OCT stratus) at baseline, 3 and 6 months of treatment and follow-up. All patients will be again tested at 3 and 6 months after changing, in a cross-over design, placebo with drug assumption and vice versa.
Main outcome measure will be pattern electroretinogram amplitude. Secondary measures will be Humphrey perimetry mean deviation and corrected pattern standard deviation, and the thickness of optic nerve fibers measured by OCT.
Pattern Electroretinogram recordings.
Stimuli will be horizontal gratings of 1.6 cycles/degree spatial frequency, modulated in counterphase at 8.14 Hz and electronically generated on a high-resolution TV monitor (contrast: 70%; mean luminance: 80 cd/m2; field size: 31° [width] x 24° [height]). Subjects fixate at the center of the stimulating field with natural pupils, whose size will be measured, at a viewing distance of 57 cm. The subjects or patients will wear full refractive correction for the test distance. Signals will be recorded by a standard, flat-cup, 9 mm Ag/AgCl electrode taped on the skin of the lower eyelid. A similar electrode, placed over the eyelid of the contralateral, unstimulated eye, will be used as reference. Responses will be amplified (100, 000), bandpass filtered (1-30 Hz), sampled with a resolution of 12 bits and averaged (250 events) with automatic artifact rejection. Two replications will be obtained for each record to verify reproducibility. Peak-to-peak amplitude (in microV) of the Fourier analyzed response 2nd harmonic will be measured.
Retinal Nerve Fiber Thickness by OCT
All patients will undergo OCT imaging (software version 4.0.1, Carl Zeiss Meditec Ophthalmic Systems Inc, Dublin, CA) of the peripapillary RNFL. The instrument will be properly aligned after the subjects are comfortably seated with their head and chin firmly positioned against the relative rests. The OCT lens will be adjusted for the patient's refractive error. The subject will be instructed to stare at the internal fixation target with the eye under examination, to enable the optic disc to come into the window and to be successively centered. The Z-offset and the polarization will be adjusted to optimize the axial interval to the OCT scan and to maximize the reflective signal, respectively. The scan protocol will be the fast RNFL thickness 3.4 (3 circular scans consecutively performed, each 3.46 mm in diameter, centered on the optic disc and averaged to form a mean baseline). All scans will be acquired five times per eye during the same day, with short breaks between measurements, under dark room conditions. Images with eye movements during scans, poor centration, poor focus, or a signal strength less than 7/10 were excluded. The mean of 3 separate RNFL measurements (256 A-scans each) with the best optic disc centration, reproducibility of the signal profiles and signal strength will be used. Retinal thickness will be measured with the location of the vitreoretinal interface and the retinal pigment epithelium defining the inner and outer boundaries of the retina, respectively. The boundaries of the RNFL will be defined by first determining the thickness of the neurosensory retina. The location of the posterior boundary of the RNFL will be determined by evaluating each A-scan for a threshold chosen to be 15 dB greater than the filtered maximum reflectivity of the adjacent retina. Various machine-generated parameters will be used for evaluation of RNFL thickness, including RNFL average thickness over the entire cylindrical section and average RNFL thickness in each quadrant (inferior, superior, temporal and nasal). Abnormal RNFL measurements using OCT will be defined as mean or quadrantic thickness values outside 95% normal limits, based on the instrument's normative age-matched database, that will be confirmed on at least three out of five repeat scans. The reference values obtained from the normal control group included in the study will be also considered. The average RNFL thickness, inferior RNFL thickness, and the superior RNFL thickness have been shown to be the best discriminators for glaucoma by the Stratus OCT. These three measures will be the RNFL parameters analyzed in our study. One author (DM) will perform all the image acquisitions.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
Who may qualify
- Ages
- 35 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- IOP > 21 mmHg at the time of diagnosis
- Response to ipotensive therapy
- No visible alterations of the optical nerve head (if OHT)
- Visual field: normal (if OHT), < -6dB at diagnosis (if POAG)
- Alterations in PERG
Key exclusion criteria (4 listed)
- Change of ipotensive therapy
- Ocular surgery
- Other ocular pathologies
- Smokers
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Epigallocatechin-gallate | Drug | – |
Primary outcome
PERG
Time frame: six months
2 secondary outcomes
IOP
Time frame: six months
Optical Coherence Tomography measurements of retinal nerve fiber layer thickness
Time frame: six months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 May 2007.
- Background: PubMed 10440253Salgarello T, Colotto A, Falsini B, Buzzonetti L, Cesari L, Iarossi G, Scullica L. Correlation of pattern electroretinogram with optic disc cup shape in ocular hypertension. Invest Ophthalmol Vis Sci. 1999 Aug;40(9):1989-97.
- Background: PubMed 10892864Colotto A, Falsini B, Salgarello T, Iarossi G, Galan ME, Scullica L. Photopic negative response of the human ERG: losses associated with glaucomatous damage. Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2205-11.
- Derived from this study: PubMed 19290537Falsini B, Marangoni D, Salgarello T, Stifano G, Montrone L, Di Landro S, Guccione L, Balestrazzi E, Colotto A. Effect of epigallocatechin-gallate on inner retinal function in ocular hypertension and glaucoma: a short-term study by pattern electroretinogram. Graefes Arch Clin Exp Ophthalmol. 2009 Sep;247(9):1223-33. doi: 10.1007/s00417-009-1064-z. Epub 2009 Mar 17.
Related trials for Primary Open Angle Glaucoma
RecruitingPhase 2
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Recruiting
The Acute Effect of Exercise Type And Timing on Ambulatory Blood Pressure and Intra-Ocular Pressure in Individuals With Glaucoma (The ACHIEVE-project).
Glaucoma Open-Angle Primary, Hypertension
RecruitingObservational study
PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group
Primary Open Angle Glaucoma
Active, not recruitingObservational study
Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults
Primary Open Angle Glaucoma
Active, not recruitingObservational study
Impact of Glaucoma and Visual Field Loss on Life Space
Primary Open-angle Glaucoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Benedetto Falsini, MD principal investigator
Chatolic University of Sacred Heart, Roma
Tommaso Salgarello, M.D. principal investigator
Catholic University, Italy
Dario Marangoni, M.D. principal investigator
Catholic University, Italy
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing Epigallocatechin-gallate in people with Primary Open Angle Glaucoma and Ocular Hypertension, run by Catholic University of the Sacred Heart at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 21 May 2007. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Benedetto Falsini, M.D. (01139-06-3015 ext. 6344, bfalsini@rm.unicatt.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
PERG (time frame: six months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00476138, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 May 2007.